TICKERNERD
Menu
IBRXIBRXHealthcare · Biotechnology

IBRX Stock Forecast: ImmunityBio, Inc. Price Predictions for 2026-2027

Last close, 24 Sept 2026
$8.64
+0.12% on the day

The 4 Wall Street analysts covering ImmunityBio, Inc. hold a median 12-month price target of $12 — +38.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 23 Sept 2026 — in the upper half.

Market cap
$9.0B
Ticker Nerd rank
53 / 100
Median analyst target
$12
Analysts covering
4
Revenue$51.2M+93.9% y/y
Operating income−$61.7M
Net income−$230.4M
Free cash flow−$70.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.1%
1M
+14.0%
YTD
+336.4%
1Y
+245.6%
From 52W high
−25.2%
From 52W low
+336.4%
$2
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IBRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ImmunityBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Sept 2026
53 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
91
Accruals
89
Momentum
88
Revisions
53
Quality
47
Growth
45
Volatility
34
Size
16
Issuance
7

Value (91): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IBRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IBRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15Oct 25Jan 26Apr 26Jul 26IBRXHigh $15Median $12Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $12Median $12High $15

The green dot is the last close — the median target sits +38.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 June 2026HC Wainwright & Co.ReiteratesBuy$15
21 May 2026BTIGReiteratesBuy—
20 May 2026HC Wainwright & Co.ReiteratesBuy—
5 May 2026D. Boral CapitalMaintainsBuy—
21 Apr 2026D. Boral CapitalMaintainsBuy—
8 Apr 2026D. Boral CapitalMaintainsBuy—
26 Mar 2026D. Boral CapitalMaintainsBuy—
23 Mar 2026D. Boral CapitalMaintainsBuy—
17 Mar 2026D. Boral CapitalMaintainsBuy—
12 Mar 2026BTIGAssumesBuy$13
9 Mar 2026D. Boral CapitalMaintainsBuy—
4 Mar 2026Piper SandlerReiteratesOverweight—
23 Feb 2026D. Boral CapitalMaintainsBuy—
23 Feb 2026HC Wainwright & Co.MaintainsBuy—
19 Feb 2026D. Boral CapitalMaintainsBuy—
17 Feb 2026D. Boral CapitalMaintainsBuy—
26 Jan 2026HC Wainwright & Co.MaintainsBuy—
23 Jan 2026BTIGMaintainsBuy—
23 Jan 2026D. Boral CapitalMaintainsBuy—
20 Jan 2026D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IBRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IBRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Sept 2026, ImmunityBio, Inc. returned +245.6% against +17.4% for the S&P 500, dividends included.

IBRX vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250300350400Oct 25Jan 26Apr 26Jul 26IBRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IBRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

ImmunityBio, Inc. (IBRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−23.5×

Cheaper than 96% of US stocks

Price / sales
57.1×

Cheaper than 5% of US stocks

Price / book
−9.0×

Cheaper than 97% of US stocks

EV / EBITDA
−41.8×

Cheaper than 93% of US stocks

Growth & margins
Revenue growth (YoY)
93.9%

Higher than 92% of US stocks

Earnings growth (YoY)
93.9%

Higher than 83% of US stocks

Gross margin
99.4%

Higher than 99% of US stocks

Operating margin
−120.4%

Higher than 13% of US stocks

Net margin
99.3%

Higher than 99% of US stocks

Returns & dividend
Return on equity
70.3%

Higher than 95% of US stocks

Return on assets
−30.5%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ImmunityBio, Inc. (IBRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ImmunityBio, Inc. has a market value of $9.0B and an enterprise value of $9.8B.

  • Revenue in the twelve months to 30 June 2026: $165.8M. The latest quarter grew 93.9% year on year.

  • Net income over the same four quarters: −$992.4M, a −598.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.97.

  • Free cash flow in the twelve months to 30 June 2026: −$288.5M.

  • Shares outstanding: 1.1B.

  • Trailing P/E: −23.5×; forward P/E: −70.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • ImmunityBio, Inc. employs 684 people — $242K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Sept 2026

Data provided by Twelve Data

Peers

IBRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IBRXImmunityBio, Inc.$9.0B
53
CAICaris Life Sciences, Inc.$8.9B
37
CYTKCytokinetics, Inc.$9.1B
47
TGTXTG Therapeutics, Inc.$8.9B
70
PTGXProtagonist Therapeutics, Inc.$8.9B
97
ARWRArrowhead Pharmaceuticals, Inc.$9.4B
55
CRNXCrinetics Pharmaceuticals, Inc.$8.7B
—

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ImmunityBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IBRX news & analysis

ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?

Zacks Investment Research · 18 Sept 2026neutral

ImmunityBio (IBRX) rose 7.0% in the last session on higher-than-average trading volume. However, the recent trend in earnings estimate revisions may not help the stock continue moving higher in the near term.

Why it matters — The stock's recent gain is accompanied by a cautionary signal from earnings estimate revisions, which may indicate that momentum could fade in the near term for IBRX watchers.

Undercovered Dozen: Blue Owl Capital, Archer Aviation, Apollo Commercial And More

Seeking Alpha · 8 Sept 2026neutral

Seeking Alpha's Undercovered Dozen series spotlights 12 lesser-covered stocks to generate fresh investment ideas and community discussion around under-the-radar equities. Readers are encouraged to engage and share perspectives on these overlooked opportunities.

Why it matters — ImmunityBio is mentioned among a broader list of lesser-covered stocks, highlighting it as an under-the-radar name for investor attention.

Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?

Zacks Investment Research · 3 Sept 2026positive

ImmunityBio reported earnings roughly 30 days ago, and its stock has risen 9.7% since that report. The article reflects on what may come next for the company's shares following the earnings release.

Why it matters — An IBRX watcher would care because the 9.7% gain since the last earnings report signals how the market has responded to the company's latest results.

ImmunityBio: None Of The Moonshots Is Priced In

Seeking Alpha · 3 Sept 2026positive

A Seeking Alpha article discusses ImmunityBio's ANKTIVA FDA approval for BCG-unresponsive NMIBC and its pipeline expansion potential, noting that current valuation reflects success in bladder cancer while assigning limited value to systemic immunotherapy potential in NSCLC and other cancers. It highlights phase 3 NSCLC data and BCG-naïve bladder cancer trial results as near-term catalysts.

Why it matters — IBRX watchers would care because these upcoming trial results and pipeline opportunities could significantly affect how the company's prospects are valued.

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

Business Wire · 10 Aug 2026positive

ImmunityBio has appointed Dr. Jim Yong Kim, former President of the World Bank and a global health leader, as Vice Chairman. He will serve in a newly created Office of the Executive Chairman, focusing on strengthening the company's international and global relationships.

Why it matters — This appointment brings a prominent global health and leadership figure to ImmunityBio's executive team, which could enhance the company's international partnerships and credibility.

FAQ

Frequently asked questions about IBRX stock

What is the IBRX stock price forecast for 2026-2027?

The 4 Wall Street analysts covering ImmunityBio, Inc. have a median 12-month price target of $12, with estimates ranging from $12 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IBRX stock a buy right now?

Of the 4 analysts covering ImmunityBio, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ImmunityBio, Inc. 53 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IBRX?

As at 23 Sept 2026, ImmunityBio, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (91 of 100).

Will IBRX stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +38.9% from the last close, and Ticker Nerd's factor model ranks ImmunityBio, Inc. 53 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IBRX stock forecast for 2030?

No analyst covering ImmunityBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IBRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $15 over the next 12 months.

How has IBRX stock performed over the past year?

ImmunityBio, Inc. returned +245.6% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ImmunityBio, Inc. do?

ImmunityBio Inc. is a biotechnology company focused on developing and commercializing immunotherapies that activate the body’s innate and adaptive immune systems.

What is the latest news on IBRX?

The most recent item we track (Zacks Investment Research, 18 Sept 2026): "ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?". ImmunityBio (IBRX) rose 7.0% in the last session on higher-than-average trading volume. However, the recent trend in earnings estimate revisions may not help the stock continue moving higher in the near term.

Company

About ImmunityBio, Inc.

ImmunityBio Inc. is a biotechnology company focused on developing and commercializing immunotherapies that activate the body’s innate and adaptive immune systems. Its current portfolio centers on ANKTIVA, a lead biologic product used with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company also works on additional biologic platforms, including cytokine fusion proteins, DNA and vaccine vectors, NK-cell therapies, and other immunomodulators for cancer and infectious diseases. ImmunityBio’s products and research programs are aimed at addressing unmet needs in oncology and infectious disease treatment through immune-based approaches. Headquartered in San Diego, California, ImmunityBio operates as a commercial-stage company with a focus on bringing biologic therapies from development into clinical use.

CEO Mr. Richard Gerald Adcock · 684 employees · United States · https://immunitybio.com